Completed PHASE3 INTERVENTIONAL NCT00088179

Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)

A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)

Sponsor: Alexion Pharmaceuticals, Inc.

Conditions Coronary Artery Disease

Interventions pexelizumab in conjunction with CABG

Updated 11 times since 2017 Last updated: Feb 20, 2018 Started: Jul 31, 2004 Primary completion: Oct 31, 2005 Completion: Oct 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Coronary Artery Disease and is currently completed. Alexion Pharmaceuticals, Inc. leads this study, which shows 11 recorded versions since 2004 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2023 — Jul 2024 [monthly]

Completed PHASE3
Apr 2023 — Dec 2023 [monthly]

Completed PHASE3

▶ Show 6 earlier versions

Apr 2022 — Apr 2023 [monthly]

Completed PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Mar 2018 — Jun 2018 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Feb 2017 — Mar 2018 [monthly]

Active Not Recruiting PHASE3

Status: Unknown Status → Active Not Recruiting
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE3

First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alexion Pharmaceuticals, Inc.
Procter and Gamble

Data source: Alexion Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Arlington, United States , Atlanta, United States , Atlantis, United States , Austin, United States , Bakersfield, United States , Baltimore, United States , Bend, United States , Besançon, France , Birmingham, United States and 124 more locations